Feasibility of affibody molecule-based PNA-mediated radionuclide pretargeting of malignant tumors

Theranostics

Volumn 6, Issue 1, 2016, Pages 93-103

  Honarvar, Hadis ^a   Westerlund, Kristina ^b   Altai, Mohamed ^a   Sandström, Mattias ^a   Orlova, Anna ^a   Tolmachev, Vladimir ^a   Karlström, Amelie Eriksson ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

Author keywords

Affibody; HER2; Peptide nucleic acid; Radionuclide pretargeting; Scaffold protein

Indexed keywords

AFFIBODY BASED PEPTIDE NUCLEIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR 2; INDIUM 111; IODINE 125; NUCLEIC ACID; RADIOISOTOPE; SCAFFOLD PROTEIN; UNCLASSIFIED DRUG; PEPTIDE NUCLEIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BALB/C NUDE MOUSE; BINDING AFFINITY; BREAST CANCER CELL LINE; BT474 CELL LINE; CANCER CELL CULTURE; CHIMERA; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMAGING; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CANCER; SKOV 3 CELL LINE; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; NEOPLASMS; NUDE MOUSE; PROCEDURES; RADIOGRAPHY; RADIOTHERAPY; STAINING; XENOGRAFT;

ANIMALS; DISEASE MODELS, ANIMAL; HETEROGRAFTS; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; PEPTIDE NUCLEIC ACIDS; RADIOGRAPHY; RADIOISOTOPES; RADIOTHERAPY; STAINING AND LABELING;

EID: 84954489812     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.12766     Document Type: Article

References (34)

1. Milenic DE, Brady ED, Brechbiel MW. Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov. 2004; 3: 488-99.
2. Pouget JP, Navarro-Teulon I, Bardiès M, Chouin N, Cartron G, Pèlegrin A, Azria D. Clinical radioimmunotherapy-the role of radiobiology. Nat Rev Clin Oncol. 2011; 8: 720-34.
3. Hnatowich DJ, Virzi F, Rusckowski M. Investigations of avidin and biotin for imaging applications. J Nucl Med. 1987; 28: 1294-302.
4. Paganelli G, Malcoviti M, Fazio F. Monoclonal antibody pretargeting techniques for tumor localization: the avidin-biotin system. Nucl Med Commun 1991; 12: 211-234.
5. Rusckowski M, Fogarasi M, Fritz B, Hnatowich DJ. Effect of endogenous biotin on the applications of streptavidin and biotin in mice. Nucl Med Biol 1997; 24: 263-268.
6. Sharkey RM, Karacay H, Cardillo TM, Chang CH, McBride WJ, Rossi EA, Horak ID, Goldenberg DM. Improving the Delivery of Radionuclides for Imaging and Therapy of Cancer Using Pretargeting Methods. Clin Cancer Res. 2005; 11: 71097121.
7. Kuijpers WH, Bos ES, Kaspersen FM, Veeneman GH, van Boeckel CA. Specific recognition of antibody-oligonucleotide conjugates by radiolabeled antisense nucleotides: a novel approach for two-step radioimmunotherapy of cancer. Bioconjug Chem. 1993; 4: 94-102.
8. Mardirossian G, Lei K, Rusckowski M, Chang F, Qu T, Egholm M, Hnatowich DJ. In vivo hybridization of technetium-99m-labeled peptide nucleic acid (PNA). J Nucl Med. 1997; 38: 907-13.
9. Liu G, Mang'era K, Liu N, Gupta S, Rusckowski M, Hnatowich DJ. Tumor pretargeting in mice using (99m)Tc-labeled morpholino, a DNA analog. J Nucl Med. 2002; 43: 384-91.
10. van de Watering FC, Rijpkema M, Robillard M, Oyen WJ, Boerman OC. Pretargeted imaging and radioimmunotherapy of cancer using antibodies and bioorthogonal chemistry. Front Med (Lausanne). 2014; 1: 44.
11. Löfblom J, Feldwisch J, Tolmachev V, Carlsson J, Ståhl S, Frejd FY. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS letters. 2010; 584: 2678-80.
12. Ahlgren S, Tolmachev V. Radionuclide molecular imaging using Affibody molecules. Curr Pharm Biotechnol. 2010; 11: 581-9.
13. Sörensen J, Sandberg D, Sandström M, Wennborg A, Feldwisch J, Tolmachev V, et al. First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule. J Nucl Med. 2014; 55: 730-5.
14. Feldwisch J, Tolmachev V. Engineering of affibody molecules for therapy and diagnostics. Methods Mol Biol. 2012; 899: 103-26.
15. Egholm M, Buchardt O, Christensen L, Behrens C, Freier SM, Driver DA, Berg RH, Kim SK, Norden B, Nielsen PE. PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen-bonding rules. Nature. 1993; 365: 566-8.
16. Boffa LC, Menichini P, Bolognesi C, Cutrona G, Roncella S, Damonte GL, Millo E, Mariani MR, Matis S, Russo D, Ciliutti P, Ferrarini M. Lack of mutagenicity and clastogenicity of Emu-NLS targeted to a regulatory sequence of the translocated c-myc oncogene in Burkitt's lymphoma. Mutat Res. 2007; 628: 129-37.
17. Cutrona G, Boffa LC, Mariani MR, Matis S, Damonte G, Millo E, Roncella S, Ferrarini M. The peptide nucleic acid targeted to a regulatory sequence of the translocated c-myc oncogene in Burkitt's lymphoma lacks immunogenicity: follow-up characterization of PNAEmu-NLS. Oligonucleotides. 2007; 17: 146-50.
18. Upadhyay A, Ponzio NM, Pandey VN. Immunological response to peptide nucleic acid and its peptide conjugate targeted to transactivation response (TAR) region of HIV-1 RNA genome. Oligonucleotides. 2008; 18: 329-35.
19. Wang Y, Chang F, Zhang Y, Liu N, Liu G, Gupta S, Rusckowski M, Hnatowich DJ. Pretargeting with amplification using polymeric peptide nucleic acid. Bioconjug Chem. 2001; 12: 807-16.
20. Rusckowski M, Qu T, Chang F, Hnatowich DJ. Pretargeting using peptide nucleic acid. Cancer. 1997; 80: 2699-705.
21. Westerlund K, Honarvar H, Tolmachev V, Eriksson Karlström A. Design, preparation and characterization of PNA-based hybridization probes for Affibody molecule-mediated pretargeting. Bioconjug Chem. 2015; 26: 1724-36.
22. Tolmachev V, Tran TA, Rosik D, Sjöberg A, Abrahmsén L, Orlova A. Tumor targeting using affibody molecules: interplay of affinity, target expression level, and binding site composition. J Nucl Med. 2012; 53: 953-60.
23. Lundberg E, Höidén-Guthenberg I, Larsson B, Uhlén M, Gräslund T. Site-specifically conjugated anti-HER2 Affibody molecules as one-step reagents for target expression analyses on cells and xenograft samples. J Immunol Methods. 2007; 319: 53-63.
24. Wållberg H, Orlova A. Slow internalization of anti-HER2 synthetic affibody monomer 111In-DOTA-ZHER2:342-pep2: implications for development of labeled tracers. Cancer Biother Radiopharm.2008; 23: 435-42.
25. Björkelund H, Gedda L, Malmqvist M, Andersson K. Resolving the EGF-EGFR interaction characteristics through a multiple-temperature, multiple-inhibitor, real-time interaction analysis approach. Mol Clin Oncol. 2013; 1: 343-352.
26. Tolmachev V, Malmberg J, Estrada S, Eriksson O, Orlova A. Development of a 124I-labeled version of the anti-PSMA monoclonal antibody capromab for immunoPET staging of prostate cancer: Aspects of labeling chemistry and biodistribution. Int J Oncol. 2014; 44: 1998-2008.
27. Tran T, Engfeldt T, Orlova A, Widström C, Bruskin A, Tolmachev V, Karlström AE. In vivo evaluation of cysteine-based chelators for attachment of 99mTc to tumor-targeting Affibody molecules. Bioconjug Chem. 2007; 18: 549-58.
28. Kramer-Marek G, Shenoy N, Seidel J, Griffiths GL, Choyke P, Capala J. 68Ga-DOTA-affibody molecule for in vivo assessment of HER2/neu expression with PET. Eur J Nucl Med Mol Imaging. 2011; 38: 1967-76.
29. Perols A, Honarvar H, Strand J, Selvaraju R, Orlova A, Karlström AE, Tolmachev V. Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules. Bioconjug Chem. 2012; 23: 1661-70.
30. Ahlgren S, Orlova A, Wållberg H, Hansson M, Sandström M, Lewsley R, Wennborg A, Abrahmsén L, Tolmachev V, Feldwisch J. Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold. J Nucl Med. 2010; 51: 1131-8.
31. Tolmachev V, Mume E, Sjöberg S, Frejd FY, Orlova A. Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules. Eur J Nucl Med Mol Imaging. 2009; 36: 692-701.
32. Altai M, Wållberg H, Honarvar H, Strand J, Orlova A, Varasteh Z, Sandström M, Löfblom J, Larsson E, Strand SE, Lubberink M, Ståhl S, Tolmachev V. 188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors: preclinical assessment. J Nucl Med. 2014; 55: 1842-8.
33. Price EW, Orvig C. Matching chelators to radiometals for radiopharmaceuticals. Chem Soc Rev. 2014; 43: 260-90.
34. Heyerdahl H, Krogh C, Borrebæk J, Larsen Å, Dahle J. Treatment of HER2-expressing breast cancer and ovarian cancer cells with alpha particle-emitting 227Th-trastuzumab. Int J Radiat Oncol Biol Phys. 2011; 79: 563-70.